ASX - By Stock
|
SPL |
Re:
Ann: Positive DEP docetaxel Phase 2 results
|
|
Belimbing
|
133 |
28K |
1 |
19/12/23 |
19/12/23 |
ASX - By Stock
|
133
|
28K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Positive DEP docetaxel Phase 2 results
|
|
Belimbing
|
133 |
28K |
0 |
19/12/23 |
19/12/23 |
ASX - By Stock
|
133
|
28K
|
0
|
|
ASX - By Stock
|
GTG |
Re:
GTG/GENE Stock Performance
|
|
Belimbing
|
16 |
4.2K |
2 |
23/11/23 |
23/11/23 |
ASX - By Stock
|
16
|
4.2K
|
2
|
|
ASX - By Stock
|
GTG |
Re:
Ann: MRFF Grant Names GTG as Sole Industry Partner
|
|
Belimbing
|
3 |
1.7K |
0 |
11/09/23 |
11/09/23 |
ASX - By Stock
|
3
|
1.7K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Ann: SPL to receive $6.5M from Mundipharma and VivaGel BV rights
|
|
Belimbing
|
36 |
10K |
0 |
14/08/23 |
14/08/23 |
ASX - By Stock
|
36
|
10K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Ann: SPL to receive $6.5M from Mundipharma and VivaGel BV rights
|
|
Belimbing
|
36 |
10K |
2 |
14/08/23 |
14/08/23 |
ASX - By Stock
|
36
|
10K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Where is the bottom??
|
|
Belimbing
|
148 |
47K |
1 |
07/08/23 |
07/08/23 |
ASX - By Stock
|
148
|
47K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
News: SPL Starpharma Holdings Says Astrazeneca Has Made Decision To Discontinue Development Of...
|
|
Belimbing
|
2 |
1.2K |
3 |
31/07/23 |
31/07/23 |
ASX - By Stock
|
2
|
1.2K
|
3
|
|
ASX - By Stock
|
GTG |
Re:
News: GTG Genetic Technologies Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
|
|
Belimbing
|
3 |
1.1K |
0 |
26/07/23 |
26/07/23 |
ASX - By Stock
|
3
|
1.1K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Where is Docetaxel heading with lung cancer?
|
|
Belimbing
|
12 |
3.3K |
0 |
05/07/23 |
05/07/23 |
ASX - By Stock
|
12
|
3.3K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Astrazeneca-showcases-scientific-advances
|
|
Belimbing
|
3 |
1.1K |
0 |
06/06/23 |
06/06/23 |
ASX - By Stock
|
3
|
1.1K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Where is the bottom??
|
|
Belimbing
|
148 |
47K |
2 |
01/06/23 |
01/06/23 |
ASX - By Stock
|
148
|
47K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
In trial assets
|
|
Belimbing
|
13 |
2.7K |
7 |
30/05/23 |
30/05/23 |
ASX - By Stock
|
13
|
2.7K
|
7
|
|
ASX - By Stock
|
SPL |
Re:
I dare you
|
|
Belimbing
|
14 |
3.3K |
1 |
17/05/23 |
17/05/23 |
ASX - By Stock
|
14
|
3.3K
|
1
|
|
ASX - By Stock
|
SPL |
I dare you
|
|
Belimbing
|
14 |
3.3K |
0 |
16/05/23 |
16/05/23 |
ASX - By Stock
|
14
|
3.3K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Mckesson UK and AURELIUS
|
|
Belimbing
|
107 |
24K |
0 |
06/04/23 |
06/04/23 |
ASX - By Stock
|
107
|
24K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Starpharma presents at ASX Small and Mid-Cap Conference
|
|
Belimbing
|
49 |
12K |
6 |
23/03/23 |
23/03/23 |
ASX - By Stock
|
49
|
12K
|
6
|
|
ASX - By Stock
|
SPL |
Re:
Mckesson UK and AURELIUS
|
|
Belimbing
|
107 |
24K |
1 |
23/03/23 |
23/03/23 |
ASX - By Stock
|
107
|
24K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Mckesson UK and AURELIUS
|
|
Belimbing
|
107 |
24K |
0 |
23/03/23 |
23/03/23 |
ASX - By Stock
|
107
|
24K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Mckesson UK and AURELIUS
|
|
Belimbing
|
107 |
24K |
1 |
23/03/23 |
23/03/23 |
ASX - By Stock
|
107
|
24K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Mckesson UK and AURELIUS
|
|
Belimbing
|
107 |
24K |
0 |
17/03/23 |
17/03/23 |
ASX - By Stock
|
107
|
24K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
The current state of play
|
|
Belimbing
|
14 |
5.5K |
3 |
02/03/23 |
02/03/23 |
ASX - By Stock
|
14
|
5.5K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
https://clinicaltrials.gov/ct2/show/NCT05205161
|
|
Belimbing
|
20 |
4.5K |
0 |
01/03/23 |
01/03/23 |
ASX - By Stock
|
20
|
4.5K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
https://clinicaltrials.gov/ct2/show/NCT05205161
|
|
Belimbing
|
20 |
4.5K |
0 |
01/03/23 |
01/03/23 |
ASX - By Stock
|
20
|
4.5K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
https://clinicaltrials.gov/ct2/show/NCT05205161
|
|
Belimbing
|
20 |
4.5K |
0 |
01/03/23 |
01/03/23 |
ASX - By Stock
|
20
|
4.5K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
https://clinicaltrials.gov/ct2/show/NCT05205161
|
|
Belimbing
|
20 |
4.5K |
0 |
01/03/23 |
01/03/23 |
ASX - By Stock
|
20
|
4.5K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Interim Report and Half-Year Financial Results
|
|
Belimbing
|
47 |
12K |
0 |
01/03/23 |
01/03/23 |
ASX - By Stock
|
47
|
12K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
https://clinicaltrials.gov/ct2/show/NCT05205161
|
|
Belimbing
|
20 |
4.5K |
1 |
01/03/23 |
01/03/23 |
ASX - By Stock
|
20
|
4.5K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Interim Report and Half-Year Financial Results
|
|
Belimbing
|
47 |
12K |
0 |
01/03/23 |
01/03/23 |
ASX - By Stock
|
47
|
12K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Genentech and milestone payments
|
|
Belimbing
|
3 |
1.0K |
0 |
27/02/23 |
27/02/23 |
ASX - By Stock
|
3
|
1.0K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Top 20 top up?
|
|
Belimbing
|
52 |
13K |
0 |
21/02/23 |
21/02/23 |
ASX - By Stock
|
52
|
13K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
A winning spl stratagy explained
|
|
Belimbing
|
21 |
4.4K |
1 |
21/02/23 |
21/02/23 |
ASX - By Stock
|
21
|
4.4K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Verified 01 January 2023 by AstraZeneca
|
|
Belimbing
|
5 |
1.9K |
3 |
12/02/23 |
12/02/23 |
ASX - By Stock
|
5
|
1.9K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
Verified 01 January 2023 by AstraZeneca
|
|
Belimbing
|
5 |
1.9K |
0 |
12/02/23 |
12/02/23 |
ASX - By Stock
|
5
|
1.9K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Pascal Soriot and Starpharma
|
|
Belimbing
|
16 |
4.3K |
1 |
08/02/23 |
08/02/23 |
ASX - By Stock
|
16
|
4.3K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Quarterly Activities Report & Appendix 4C
|
|
Belimbing
|
25 |
7.2K |
0 |
06/02/23 |
06/02/23 |
ASX - By Stock
|
25
|
7.2K
|
0
|
|
ASX - By Stock
|
GTG |
Re:
Ann: Appendix 3Y Change of Directors Interest Notice
|
|
Belimbing
|
3 |
923 |
0 |
02/02/23 |
02/02/23 |
ASX - By Stock
|
3
|
923
|
0
|
|
ASX - By Stock
|
GTG |
Re:
Ann: Appendix 4C and Quarterly Business Update December 2022
|
|
Belimbing
|
10 |
2.6K |
3 |
31/01/23 |
31/01/23 |
ASX - By Stock
|
10
|
2.6K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
Everyone locked and loaded???
|
|
Belimbing
|
28 |
9.1K |
8 |
26/01/23 |
26/01/23 |
ASX - By Stock
|
28
|
9.1K
|
8
|
|
ASX - By Stock
|
GTG |
When will the Appendix 4C come out?
|
|
Belimbing
|
0 |
336 |
2 |
18/01/23 |
18/01/23 |
ASX - By Stock
|
0
|
336
|
2
|
|
ASX - By Stock
|
GTG |
Re:
What's everyone doing with their GTG holdings?
|
|
Belimbing
|
6 |
3.7K |
1 |
13/01/23 |
13/01/23 |
ASX - By Stock
|
6
|
3.7K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Hidden 200 k order
|
|
Belimbing
|
1 |
514 |
0 |
11/01/23 |
11/01/23 |
ASX - By Stock
|
1
|
514
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Great Expectations
|
|
Belimbing
|
11 |
3.4K |
0 |
05/01/23 |
05/01/23 |
ASX - By Stock
|
11
|
3.4K
|
0
|
|
ASX - By Stock
|
GTG |
Re:
What's everyone doing with their GTG holdings?
|
|
Belimbing
|
6 |
3.7K |
1 |
19/12/22 |
19/12/22 |
ASX - By Stock
|
6
|
3.7K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Viraleze Sales Numbers
|
|
Belimbing
|
24 |
6.1K |
3 |
12/12/22 |
12/12/22 |
ASX - By Stock
|
24
|
6.1K
|
3
|
|
ASX - By Stock
|
GTG |
Re:
Competitor Activity
|
|
Belimbing
|
2 |
1.0K |
5 |
30/11/22 |
30/11/22 |
ASX - By Stock
|
2
|
1.0K
|
5
|
|
ASX - By Stock
|
GTG |
Competitor Activity
|
|
Belimbing
|
2 |
1.0K |
1 |
30/11/22 |
30/11/22 |
ASX - By Stock
|
2
|
1.0K
|
1
|
|
ASX - By Stock
|
GTG |
Re:
Ann: AGM Presentation and Chairman's Address
|
|
Belimbing
|
9 |
2.8K |
0 |
30/11/22 |
30/11/22 |
ASX - By Stock
|
9
|
2.8K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Ann: VIRALEZE launched in Hong Kong and Macau
|
|
Belimbing
|
111 |
26K |
6 |
23/11/22 |
23/11/22 |
ASX - By Stock
|
111
|
26K
|
6
|
|
ASX - By Stock
|
GTG |
Re:
Ann: Genetic Technologies Investor Presentation Webinar
|
|
Belimbing
|
7 |
2.7K |
2 |
14/11/22 |
14/11/22 |
ASX - By Stock
|
7
|
2.7K
|
2
|
|